Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;21(1):55-63.
doi: 10.1007/s12094-018-1980-7. Epub 2018 Dec 7.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

E González-Flores  1 , R Serrano  2 , I Sevilla  3 , A Viúdez  4 , J Barriuso  5   6 , M Benavent  7 , J Capdevila  8 , P Jimenez-Fonseca  9 , C López  10 , R Garcia-Carbonero  11
Affiliations

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

E González-Flores et al. Clin Transl Oncol. 2019 Jan.

Abstract

NENs are a heterogeneous family of tumors of challenging diagnosis and clinical management. Their incidence and prevalence continue to rise across all sites, stages and grades. Although improved diagnostic techniques have led to earlier detection and stage migration, the improved prognosis documented over time for advanced gastrointestinal and pancreatic neuroendocrine tumors also reflect improvements in therapy. The aim of this guideline is to update practical recommendations for the diagnosis and treatment of gastroenteropancreatic and lung NENs. Diagnostic procedures, histological classification and therapeutic options are briefly discussed, including surgery, liver-directed therapy, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, and treatment algorithms are provided.

Keywords: Diagnosis; Gastroenteropancreatic; Guidelines; Lung; Neuroendocrine neoplasms; Neuroendocrine tumors; Therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

EGF reports Advisory from Pfizer, Novartis, Ipsen and AAA, outside the submitted work. RS reports Advisory from Pfizer, Novartis and Ipsen, outside the submitted work. IS reports Advisory from Pfizer, Novartis and Ipsen, outside the submitted work. AV has nothing to disclose. JB reports Grants and travel expenses from Ipsen, Pfizer, Novartis and AAA, outside the submitted work. MB has nothing to disclose. JC has nothing to disclose. PJF has nothing to disclose. CL reports personal fees and non-financial support from Pfizer, personal fees and non-financial support from IPSEN, personal fees and non-financial support from NOVARTIS, outside the submitted work. RGC has received honoraria from Ipsen, Novartis, Pfizer and AAA.

Ethical approval

The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

For this type of study, no formal consent is required.

Figures

Fig. 1
Fig. 1
a Therapeutic algorythm for G1-2 GEP NETs. b Therapeutic algorythm for typical and atypical Lung NETs
Fig. 2
Fig. 2
Therapeutic algorythm for G3 NENs
See this image and copyright information in PMC

References

    1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual A, Benavent M, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the WHO 2010. Oncologist. 2018;22:1–11. - PMC - PubMed
    1. García-Carbonero R, Vilardell F, Jiménez-Fonseca P, González-Campora R, González E, Cuatrecasas M, et al. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014;16(3):243–256. doi: 10.1007/s12094-013-1062-9. - DOI - PubMed
    1. Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs. Ann Nucl Med. 2015;29(1):1–7. doi: 10.1007/s12149-014-0898-6. - DOI - PMC - PubMed
    1. Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186–192. doi: 10.1007/s12022-014-9313-z. - DOI - PubMed

MeSH terms